RecruitingNot ApplicableNCT05874674
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study
Sponsor
Wonju Severance Christian Hospital
Enrollment
100 participants
Start Date
Dec 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Comparison nafamostat and low molecular weight heparin among dialysis patients
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria1
- platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month
Exclusion Criteria1
- cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNafamostat Mesylate
Comparison effect of nafamostat and cnoxan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05874674
Related Trials
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor
NCT045557851 location
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
NCT066579241 location
Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)
NCT068903121 location
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT063378383 locations
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT0426303840 locations